MustGrow Biologics Corp. (TSXV:MGRO)
Canada · Delayed Price · Currency is CAD | Market Cap | 29.94M -19.5% |
| Revenue (ttm) | 8.38M +2,006.6% |
| Net Income | -6.94M |
| EPS | -0.12 |
| Shares Out | 70.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,217 |
| Open | 0.3800 |
| Previous Close | 0.4300 |
| Day's Range | 0.3800 - 0.4350 |
| 52-Week Range | 0.2900 - 0.9400 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About MustGrow Biologics
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage... [Read more]
Financial Performance
In 2025, MustGrow Biologics's revenue was 8.29 million, an increase of 1981.95% compared to the previous year's 398,018. Losses were -7.26 million, 48.5% more than in 2024.
Financial StatementsNews
MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 202...
MustGrow Closes $3.7 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its pre...
MustGrow Increases Non-Brokered LIFE Offering to Approximately $3.7 Million
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Saskatoon, Saskatchewan--(Newsfile Corp. - June 17, 2026) - MustGrow Biologics Corp. (TSXV...
MustGrow Biologics Slides: Corporate presentation
MustGrow Biologics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
MustGrow Biologics Earnings Call Transcript: Q1 2026
Q1 2026 saw the first TerraSante sales, improved margins, and a narrowed focus after discontinuing NexusBioAg. Manufacturing issues limited Q1 growth, but demand is strong and management expects a stronger second half, with international expansion and capital raises supporting growth.
MustGrow Biologics Earnings release: Q1 2026
MustGrow Biologics released its Q1 2026 earnings on May 29, 2026, summarizing the period's financial results.
MustGrow Announces First Quarter 2026 Financial Results
Investor Webcast: Friday, May 29 th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/7717781882447/WN_m6cQAgeQSD6hjP6JeVpfbw Please join/register at least 5 minute...
MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - May 25, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered private p...
MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product
MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSante TM . Based on infield grower data, the mustard-...
MustGrow Announces Market Awareness Services and Investor Relations Agreements
Saskatoon, Saskatchewan--(Newsfile Corp. - May 14, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") announces the following market awareness servic...
MustGrow Biologics Earnings Call Transcript: Q4 2025
2025 sales fell short due to NexusBioAg underperformance, but TerraSante sales surged 377% year-over-year. Focus is now on expanding TerraSante in the U.S. and globally, with improved margins expected in 2026 and cash flow breakeven targeted for 2027.
MustGrow Biologics Earnings release: Q4 2025
MustGrow Biologics released its Q4 2025 earnings on April 30, 2026, summarizing the period's financial results.
MustGrow Announces 2025 Financial Results
Investor Webcast: Thursday, April 30 th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/3117774401744/WN_eXcymymWSnicArxMPOiZVA Please join/register at least 5 mi...
MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product
MustGrow has received approval from the Georgia Department of Agriculture to commence sales of TerraSante ™ , an organic biofertility product, in the State of Georgia. Mustard-derived TerraSante™ has ...
MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems
MustGrow's mustard-derived organic biocontrol technology TerraMG TM focuses on soil-borne disease and pest suppression, which has been shown to improve soil conditions, crop yields, and healthier root...
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
Saskatoon, Saskatchewan--(Newsfile Corp. - January 23, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce: the closing of its...
MustGrow Announces Non-Brokered LIFE Offering of up to $2 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - January 8, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered privat...
MustGrow Reports Significant U.S. Potato Yield and Economic Performance in Large Scale Field Trials Utilizing TerraSante(TM)
Mustard-derived organic TerraSante TM focuses on crop yields, soil and soil microbiome health, and nutrient/water use efficiencies; Large scale field trial showed 2 ton per acre yield increase with la...
MustGrow Biologics Earnings Call Transcript: Q3 2025
Q3 2025 saw seasonally low sales and no TerraSate revenue due to inventory shortages, but gross margin improved to 22%. Strong demand for TerraSate and new product launches are expected to drive a robust Q4 and a positive outlook for 2026, with break-even targeted next year.
MustGrow Biologics Earnings release: Q3 2025
MustGrow Biologics released its Q3 2025 earnings on November 26, 2025, summarizing the period's financial results.
MustGrow Announces Record Q3-2025 Results
Investor Webcast: Wednesday, November 26th at 4:00pm ET / 1:00pm PT. Register/View Here: https://us02web.zoom.us/webinar/register/8617635107958/WN_Ka6aNlTZTLuCJPaetQoLuQ.Please join/register at least ...
MustGrow Biologics Slides: Corporate Presentation
MustGrow Biologics has posted slides in relation to its latest quarterly earnings report, which was published on November 7, 2025.
MustGrow Announces Grant of RSUs and DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directo...
MustGrow Secures $2 Million Line of Credit with CIBC; Guaranteed by EDC
Saskatoon, Saskatchewan--(Newsfile Corp. - September 10, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce it has secured a $...
MustGrow Closes Non-Brokered LIFE Offering of Approximately $2.1 Million, Repricing of Warrants, and Shares for Debt Settlement
Saskatoon, Saskatchewan--(Newsfile Corp. - August 29, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce: (i) the closing of ...